Skip to main content
Tuesday 3 June 2025
twitter linkedin facebook rss
User account menu
  • Subscribe
Home
Pharmaphorum menu first category
  • News
  • Views & Analysis
  • Deep Dive
    • Research & Development
    • Market Access
    • Oncology
    • Artificial Intelligence
    • Patients & Partnerships
    • Commercialisation
    • Previous Editions
  • Webinars
  • Podcasts
  • Videos
  • White Papers
  • Events
Pharmaphorum
close
    SECTION
    • News
    • Views & Analysis
    • Deep Dive
      • Research & Development
      • Market Access
      • Oncology
      • Artificial Intelligence
      • Patients & Partnerships
      • Commercialisation
      • Previous Editions
    • Webinars
    • Podcasts
    • Videos
    • White Papers
    • Events
Channels
    Channels
    • Sales & Marketing
    • R&D
    • Digital
    • Market Access
    • Oncology
    • Patients
    • Spotlight On
Channels
  • Sales & Marketing
  • R&D
  • Digital
  • Market Access
  • Oncology
  • Patients
  • Spotlight On
    SUB NAVIGATION
    • Live Coverage
    • Partner Content
    • About us
    • Work for us
    • Contribute
    • Contact us
    • Advertise

Newsletters and Deep Dive digital magazine

 
 
Sign up
twitter linkedin facebook rss
Sign in

Deep Dive

Market Access
Benjamin Franklin face on USD dollar

How Trump's pharma tariffs will hurt industry and patients a...

Market Access
hexagon world illustration

The evolution of real-world evidence

Market Access
colour curve

The smarter spending playbook: Reviving stagnant pharma prod...

Market Access
Healthcare system illustration

From market access to real-world patient access: Closing the...

Market Access
Healthcare and medical concept visual

Demystifying market access: Inside the complex journey from ...

Market Access
three blocks on red background

JCA readiness: How to prepare for success in the new EU HTA ...

  • Load more results

Editor's Picks

  1. Astellas adds to claudin clout with $1.3bn+ Evopoint deal
  2. ASCO 25: Regeneron hails Libtayo's adjuvant data in CSCC
  3. ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC
  4. Moderna's $760m-plus flu vaccine contracts are nixed by HHS
  5. MSD and Daiichi Sankyo pull HER3-DXd's FDA filing
Oncology
ASCO 2025 Karen Rodriguez-Lorenc

Regeneron at ASCO 25: Advancing multiple myeloma treatment

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png
Market Access
Bridging research and clinical guidelines
Sponsored

Bridging research and clinical guidelines – interactive stra...

Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.

Pharmaphorum Menu
  • Digital
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Market Access
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Oncology
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Patients
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • R&D
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Sales & Marketing
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Spotlight on
    • ASCO 2025
    • Frontiers Health 2024
    • Life Science Industry Report
    • World Without Disease Summit

Sign up for email newsletters and Deep Dive

Subscribe
 
 
rss facebook linkedin twitter
Pharmaphorum
About us Advertising Contact us
Contribute Cookie Policy Privacy Policy
Terms & Conditions Work for us
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company